Prevalence of Delayed Chemotherapy Associated Nausea

Study Overview
=================
Brief Summary
-----------------
This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.

Detailed Description
-----------------
Chemotherapies are rated to have a high to minimal emetogenic potential in oncology patients. Their potential to induce delayed nausea is supposed to often be higher than their emetogenic potential. However, data on delayed chemotherapy-related nausea are scarce, which is problematic because nausea (a) has a large impact on patients quality of life and treatment decisions, (b) is often underestimated by health care professionals, (c) is less responsive to commonly used antiemetic medication, and (d) may even be different from rates that have been established in controlled clinical trials. Therefore, the aim of this study is to assess the prevalence of delayed chemotherappy-induced nausea in adult oncology patients in dayclinics.

Official Title
-----------------
Delayed Chemotherapy-induced Nausea: A Multi-center Prevalence Survey in Adult Oncology Patients in Clinical Practice

Conditions
-----------------
Chemotherapy-induced Nausea and Vomiting

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first day of chemotherapy of a new cycle (any cycle) speak and write German sign the consent forms Exclusion Criteria: cognitive or linguistic impairments that would significantly impede consent or participation (as assessed by the nurses in charge) accompanying radiotherapy; pre-existing nausea within three days before the start of the first chemotherapy in this cycle; and prior participation in CINrate (each person participates only once)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| delayed Nausea | nausea that occurs 24 hours to 5 days after chemotherapy (100mm VAS in diary) | Each patient: each days for 5 days after chemotherapy; recruitment: six weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acute nausea | nausea that occurs within 24 hours of chemotherapy (100mm VAS in diary) | Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks | 
| acute and delayed vomiting | vomiting that occurs within 5 days of chemotherapy (100mm VAS in diary) | Each patient: each day for 5 days after chemotherapy; recruitment: six weeks | 
| adherence to antiemetics | prescribed antiemetics compared with taken antiemetics; intake is calculated in % of the correct dose (dosing adherence) and in % of the dose at the right time (timing adherence) | Each patient: each day for 5 days after chemotherapy; recruitment: six weeks | 
| antiemetic prescription | antiemetic medication that is prescribed | Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks | 
| interference of nausea or vomiting with everyday life | Functional Living Index Cancer (FLIE) | Each patient: measured at day 5 after chemotherapy; recruitment: six weeks | 
| patient-related barriers to antiemetics | Nausea and Vomiting Management Barriers Questionnaire (NVMBQ) | Each patient: measured at day 5 after chemotherapy; recruitment: six weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prevalence, chemotherapy-induced nausea and vomiting, oncology, suportive care